Is AbbVie the Best Dividend King to Buy in September?

AbbVie has increased its dividend for 54 consecutive years, including its Abbott Laboratories legacy, and is positioned to continue dividend growth despite Humira's 2023 U.S. patent-expiry headwind. The company returned to revenue and earnings growth by leveraging its $63 billion Allergan acquisition and growth drugs Skyrizi and Rinvoq, while advancing replacement pipeline candidates including eczema drug Zumilokibart, weight-loss candidate ABBV-295, and cancer therapy ABBV-706. The article views AbbVie as a strong dividend option, though it notes patent-cliff and regulatory risks make it unsuitable for every investor.

Analysis

ABBV’s investable question is not dividend pedigree; it is whether the market has fully capitalized the post-Humira replacement cycle. Durable growth in Skyrizi/Rinvoq can support operating leverage and renewed multiple confidence over the next 1-3 quarters, but the same concentration creates a higher earnings-revision beta than the dividend framing suggests. The relevant KPI is franchise growth relative to consensus, not the quarterly dividend increase.

The second-order risk is that AbbVie’s immunology success draws increasingly intense competition in inflammatory bowel disease and dermatology, where efficacy, safety labeling, payer access, and formulation convenience can shift share faster than a nominal patent timeline implies. JAK-class safety scrutiny remains a particular risk for Rinvoq, while pricing pressure from commercial payers and Medicare negotiation policy could limit incremental-margin conversion even if prescription volumes remain strong. Pipeline and business-development assets should be valued as upside optionality until late-stage data, regulatory clarity, and launch economics are independently established.

Relative to JNJ and ABT, ABBV offers greater near-term earnings torque but also more pipeline, indication-expansion, and eventual loss-of-exclusivity risk. Consensus may underappreciate that a successful replacement of one patent cliff does not eliminate the equity’s recurring “next cliff” discount; this can cap multiple expansion as investors look toward the end of the decade. Conversely, sustained beats on immunology growth plus stable aesthetics demand could compress that discount over the next 6-18 months.

Key Decisions for Investors

• Maintain or initiate ABBV only on a pullback or after the next earnings release confirms immunology franchise growth above consensus and no reduction in full-year EPS/FCF guidance; target a 6-12 month 10-15% total-return profile including dividend, with a thesis stop on material franchise-growth deceleration or reduced guidance.
• For defensive healthcare exposure, express the higher-conviction relative view as long ABBV / short JNJ in equal dollar amounts for 3-6 months if ABBV’s immunology sales continue to outgrow expectations; exit if Rinvoq safety language worsens, payer restrictions rise, or the relative spread moves adversely by roughly 10%.
• Do not underwrite meaningful value for obesity, oncology, or dermatology pipeline candidates before pivotal data and commercial terms are disclosed; set event alerts around Phase 3 readouts and regulatory updates rather than buying optionality today.
• Use JNJ or ABT rather than ABBV for portfolios prioritizing lower patent-cliff and single-franchise risk; ABBV’s dividend yield should not be treated as compensation for an unmonitored concentration risk.